| |
Oxford
BioMedica (LSE: OXB) is a biopharmaceutical
company specialising in the development
of gene-based products for a range of
unmet medical needs with an emphasis
on new cancer products, which combine
novel mechanisms of action with very
low side effects, and innovative neurotherapy
products, which address large and, in
several areas, untapped markets. The
products are all protected by multiple
patents comprising a total intellectual
property portfolio of approximately 70
patent families.
In
addition to its technical research skill-base,
Oxford BioMedica has in-house
clinical, regulatory and manufacturing
know-how. The development pipeline includes
two novel anti-cancer products in clinical
trials and a gene-based treatment for Parkinson’s
disease, which is in late preclinical studies.
TroVax®, Oxford BioMedica’s
lead cancer immunotherapy product, is in
Phase II trials for colorectal cancer.
A further Phase II trial in Renal cancer
is awaiting final approval in the US, having
already received approval from the Recombinant
DNA Advisory Committee (RAC). Further Phase
II trials are planned for colorectal and
breast cancer. MetXia®, Oxford BioMedica’s
lead gene-based cancer therapeutic, is
based on a highly engineered retrovirus
gene delivery system expressing a specific
human cytochrome P450 gene. MetXia is being
investigated in a Phase I/II trial in breast
cancer, and is awaiting final approval
to start further clinical trials in pancreatic
cancer, having already received approval
from the Gene Therapy Advisory Committee
(GTAC).
Oxford BioMedica has a wholly owned subsidiary
in San Diego, USA. Oxford BioMedica has
corporate collaborations with Wyeth, Intervet,
Kiadis, Amersham, Arius Research and Viragen.
|
 |
King's
is one of the oldest and largest colleges
of the University of London with some
13,400 undergraduate students and some
5,000 postgraduates in ten schools of
study. The College had 24 of its subject-areas
awarded the highest rating of 5* and
5 for research quality, demonstrating
excellence at an international level.
It is in the top group of five universities
for research earnings and has an annual
turnover of £320 million and research
income from grants and contracts of some £90
million
(2001-2002). King's is a member of the Russell
Group, a coalition of the UK's major research-based
universities.
|
